Bastepe M., Frohlich L.E, Hendy G.N., Indridason O.S., Josse R.G., Koshiyama H., Korkko J., Nakamoto J.M., Rosenbloom A.L., Slyper A.H., et al., 2003. Autosomal dominant pseudohypoparathyroidism type lb is associated with a heterozygous microdeletion that likely disrupts a putative imprinting control element of
Bembe N.G., Mangelsdorf M., Jagla M., Vanderluit J., Garrick D., Gibbons R.J., Higgs D.R., Slack R.S., and Picketts D.J., 2005. The chro-matin-remodeling protein ATRX is critical for neuronal survival during corticogenesis.
Bickmore W.A. and van der Maarel S.M., 2003. Perturbations of chromatin structure in human genetic disease: Recent advances.
Boerkoel C.E, Takashima H., John J., Yan J., Stankiewicz P., Rosen-barker L., Andre J.L., Bogdanovic R., Burguet A., Cockfield S., et al., 2002. Mutant chromatin remodeling protein SMAR-CAL1 causes Schimke immuno-osseous dysplasia.
Bottiglieri T., Hyland K., and Reynolds E.H., 1994. The clinical potential of ademethionine (S-adenosylmethionine) in neurological disorders.
Botto L.D. and Yang Q., 2000. 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: A HuGE review.
Brattstrom L., Wilcken D.E., Ohrvik J., and Brudin L., 1998. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: The result of a meta-analysis.
Brown V., Jin P., Ceman S., Darnell J.C., O’Donnell W.T., Tenen-baum S.A., Jin X., Feng Y., Wilkinson K.D., Keene J.D., et al., 2001. Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome.
Carney R.M., Wolpert CM., Ravan S.A., Shahbazian M., Ashley-Koch A., Cuccaro M.L., Vance J.M., and Pericak-Vance M.A., 2003. Identification of MeCP2 mutations in a series of females with autistic disorder.
Caspary T., Cleary M.A., Perlman E.J., Zhang P., Elledge S.J., and Tilgh-man S.M., 1999. Oppositely imprinted genes
Caudy A.A., Myers M., Hannon G.J., and Hammond S.M., 2002. Fragile X-related protein and VIG associate with the RNA interference machinery.
Chen J., Giovannucci E.L., and Hunter D.J., 1999. MTHFR polymorphism, methyl-replete diets and the risk of colorectal carcinoma and adenoma among U.S. men and women: An example of gene-environment interactions in colorectal tumorigenesis.
Chen W.G., Chang Q., Lin Y., MeissnerA., West A. E., Griffith E.C., Jaenisch R., and Greenberg M.E., 2003. Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2.
Chen Z., Karaplis A.C., Ackerman S.L., Pogribny LP, Melnyk S., Lussier-Cacan S., Chen M.F., Pai A., John S.W., Smith R.S., et al., 2001. Mice deficient in methylenetetrahydrofolate reductase exhibit hyperhomocysteinemia and decreased methylation capacity, with neuropathology and aortic lipid deposition.
Chrivia J.C., Kwok R.P., Lamb N., Hagiwara M., Montminy M.R., and Goodman R.H., 1993. Phosphorylated CREB binds specifically to the nuclear protein CBP.
Coffee B., Zhang E, Warren S.T., and Reines D., 1999. Acetylated histones are associated with FMR1 in normal but not fragile X-syndrome cells (erratum
Collins A.L., Levenson J.M., Vilaythong A.P., Richman R.D., Armstrong L., Noebels J.L., Sweatt J.D.. andZoghbi H.Y., 2004. Mild overexpression of MeCP2 causes a progressive neurological disorder in mice.
Cooney C.A., 1993. Are somatic cells inherently deficient in methylation metabolism? A proposed mechanism for DNA methylation loss, senescence and aging.
CooperW.N., LuhanaA., EvansG.A., RazaH., Haire A.C., Gmndy R., Bowdin S.C., Riccio A., Sebastio G., Bliek J., et al., 2005. Molecular subtypes and phenotypic expression of Beckwith-Wiedemann syndrome.
Couvert P., Bienvenu T., AquavivaC., Poirier K., Moraine C., Gen-drot C., Verloes A., Andres C., Le Fevre A.C., Souville I., et al.. 2001.